2022 Genitourinary Cancers Symposium
The 2022 Genitourinary Cancers Symposium publication includes articles and expert perspectives on the groundbreaking data presented at the 2022 Genitourinary Cancers Symposium in San Francisco, California.
Volume: 01
Issue: 01
2021 ESMO Congress: Genitourinary Cancers
The 2021 ESMO Congress priority report focuses on updates in genitourinary cancers presented at the virtual conference, held September 16 to 21, 2021.
Volume: 1
Issue: 1
ASCO 2021: Updates in Genitourinary Cancers
This publication provides coverage of data in genitourinary cancers that were presented at the 2021 ASCO Annual Meeting.
2021 Genitourinary Cancers Symposium
Volume: 02
ASCO 2020: Update on Genitourinary Cancers
2020 Genitourinary Cancers Symposium
MK-1084 Alone and Plus Pembrolizumab Shows Early Safety, Activity in KRAS G12C+ Solid Tumors
First-Line Anlotinib Plus Etoposide and Carboplatin Improves PFS in ES-SCLC
Concurrent Durvalumab/CRT Does Not Confer Significant Survival Advantage in Unresectable Stage III NSCLC
Phase 2 IMscin002 Study Shows Patients With NSCLC Prefer Subcutaneous Atezolizumab